Cipla's arm inks pact for anti-psychotic drug
11th Feb 2020

Cipla's wholly-owned subsidiary -- Cipla Medpro South Africa has concluded an exclusive agreement securing originator and authorised generic brands of an atypical anti-psychotic drug, Quetiapine.

The agreement involves AstraZeneca Pharmaceuticals, the originator of the Medicine, and Luye Pharma Hong Kong, which acquired the assets and rights to the medicine in select territories. The transaction allows Cipla Medpro to market and distribute the Medicine in South Africa and neighbouring countries.

The existing portfolio consists of the originator brand Seroquel and the authorised generic brand Truvalin, medication which is used to treat mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.